SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind announced FDA approval of Afrezza (insulin human) Inhalation…

MANNKIND CORP · 8-K filed Jun 2, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 2, 2026 at 08:00 ET

MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in children and adolescents aged 6+ with type 1 and type 2 diabetes. This also fulfills the last remaining postmarketing requirement from the original 2014 approval, removing a key regulatory overhang and opening a new patient population of over 350,000 U.S. children with diabetes.

  • FDA approved Afrezza for pediatric use in patients aged 6 and older with type 1 and type 2 diabetes.
  • Over 350,000 U.S. children and adolescents live with diabetes, majority type 1 requiring lifelong insulin.
  • Pediatric sBLA fulfills the last remaining postmarketing requirement from the original June 27, 2014 approval letter.
  • Approval date: May 29, 2026; 8-K filed June 2, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access